Drug intelligence / Profile preview

Threptin

Development stage: Unknown
Lead developer: Raptakos Brett
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Threptin is a high-protein, high-calorie nutritional supplement developed and marketed by Raptakos, Brett & Co. Ltd. Originally launched in 1953, it is designed to address protein deficiency and provide nutritional support for various medical conditions and age groups. The primary protein source is casein, which has a high biological value. The product is enriched with essential vitamins (particularly B-complex), minerals, and antioxidants. It is available in several forms, including diskettes (biscuits) and powders, with specialized versions like Threptin Lite formulated for patients with diabetes or cardiac issues. It is classified as a nutraceutical rather than a pharmaceutical drug.

Brand names: ThreptinThreptin LiteThreptin Diskettes
Other names: Threptin-Raptakos Brett

Beyond the preview

Go deeper on Threptin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Threptin.

Explore the full profile